What we do

The HInM portfolio

We aim to make Greater Manchester one of the most innovative health and social care systems around the world.  Our exceptional academic and clinical assets, booming life sciences sector and the massive opportunity of devolved accountability for health and social are just some of the factors that put us in a unique position.

Health Innovation Manchester works with innovators to discover, develop and deploy new solutions that improve the health and wellbeing of Greater Manchester’s 2.8m citizens.

HInM’s innovation portfolio can be described under four main categories:

 

HInM has an active portfolio of 89 live health and care innovation projects that are being deployed in localities across GM.  They are aligned to maternity, cardiovascular, cancer, respiratory, mental health and falls prevention, as well as cross-cutting themes.  Innovations range from a digital device, optimising new or existing medication, utilising new technology or modifying practice.  All innovations are considered by the Innovation Prioritisation Committee (IPMC).

Localities are at different stages of deployment depending on local priorities and readiness.  Innovations include projects that have been determined by the GM system or nationally via projects that all AHSNs are required to adopt and spread.

HInM also operates the Greater Manchester and Eastern Cheshire Patient Safety Collaborative across GM, which provides clinical staff with training and expertise to reduce the risk of harm to patients, with a focus on maternity and neonatal care and the deteriorating patient.

 

HInM has a thriving programme of research activities across the six domains of research excellence – cancer, cardiovascular disease, inflammation and repair, women and children, mental health, and population health, and since 2014 has invested over £3.5m in the domain research projects.

HInM is now working across GM’s main research partners to focus activity to address the health and social care priorities of GM, as well as to secure further funding and advance translational research delivery into the frontline.

This activity is being further supported through the development of strategic partnerships with the University of Salford, University of Bolton and Manchester Metropolitan University and the University of Manchester.

The emergent GM industrial strategy focuses on supporting growth in high value sectors or assets that have the potential to be world-leading and globally distinctive.  One of these is ‘health innovation’, building on GM’s strengths in life sciences, medical technology/devices, health services and devolution, which is a primary function of HInM.

HInM oversees the GM strategic partnerships with the Association of the British Pharmaceutical Industry (ABPI) and the Association of the British HealthTech Industries (ABHI) to develop a strong pipeline of industry-led innovations.

HInM also operates an Innovation Nexus and support programme for SMEs to develop and embed new innovative products and solutions.

HInM’s digital transformation programme ensures that GM continues to lead the way in the development and delivery of digital solutions and tech into health and care services, which not only improves the health and wellbeing of local citizens but supports economic growth.

HInM is heavily involved in the development of the shared care record of GM as part of the Local Health and Care Record Exemplar (LHCRE) programme and is the lead agency responsible for developing and delivering a digital innovation hub for the city-region.

HInM also operates a digital accelerator programme to provide mentorship to digital tech companies and has an innovative Data Lab project with NICE to explore how routinely collected patient data may be used to evaluate the effectiveness of medicines, new technologies and interventions in the development of NICE guidance.